Argenx to Present at Upcoming Investor Conferences
Argenx to Present at Upcoming Investor Conferences
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.November 26, 2024
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.
2024年11月26日
荷蘭阿姆斯特丹 - 全球免疫學公司和納斯達克（ARGX）的argenx致力於改善患有嚴重自身免疫疾病的患者的生活，今天宣佈管理團隊成員將參加12月份以下即將舉行的投資者會議。
-
Citi's 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL.
-
7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wednesday, December 4 at 1:45 p.m. ET in Coral Gables, FL.
-
Piper Sandler's 35th Annual Healthcare Conference. Fireside chat on Thursday, December 5 at 9:00 a.m. ET in New York, NY.
- 花旗銀行2024年全球醫療保健會議。12月3日（星期二）下午1:45在佛羅里達州邁阿密舉行爐邊聊天。
- 第七屆Evercore I&I健康會議。12月4日（星期三）下午1:45在佛羅里達州科勒爾蓋布爾舉行爐邊聊天。
- Piper Sandler第35屆年度醫療保健會議。12月5日（星期四）上午9:00在紐約紐約市舉行爐邊聊天。
Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.
有關這些事件的更多信息將在argenx網站的投資者專區提供，網址爲argenx.com/investors。
About argenx
關於argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
argenx是一家全球免疫學公司，致力於改善患有嚴重自身免疫性疾病的人們的生活。通過其免疫學創新計劃（IIP）與領先的學術研究人員合作，argenx旨在將免疫學突破轉化爲世界一流的新型抗體藥物組合。argenx開發並在美國、日本、以色列、歐盟、英國、中國和加拿大全球商業化了首個獲批的新生兒Fc受體（FcRn）阻斷劑。該公司正在評估efgartigimod在多種嚴重自身免疫性疾病中的應用，並在其治療特定領域推進幾種較早期的實驗性藥物。欲了解更多信息，請訪問並關注我們的領英、推特、Instagram、Facebook和YouTube賬號。
For further information, please contact:
如需更多信息，請聯繫：
Media:
媒體:
Ben Petok
bpetok@argenx.com
Ben Petok
bpetok@argenx.com
Investors:
投資者:
Alexandra Roy (US)
aroy@argenx.com
Alexandra Roy（美國）
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
Lynn Elton（歐盟）
lelton@argenx.com
